ResMed Corp (NYSE: RMD), a leading developer, manufacturer and marketer of products for the screening, treatment and management of sleep-disordered breathing (SDB) and other respiratory disorders, announced further progress in its ongoing efforts to increase awareness and recognition of the relationship between sleep apnea and type 2 diabetes. As part of this initiative, ResMed will be driving the education of certified nurse educators by attending the American Association of Diabetes Educators (AADE) Annual Meeting for the first time in August. Diabetes educators are at the forefront of patient management for diabetes sufferers and have very little exposure to the detrimental effects of untreated sleep apnea.
The comorbidity of sleep apnea and diabetes is gaining recognition; a 2005 study showed that obstructive sleep apnea (OSA) affects 50% of male type 2 diabetes patients, a substantially higher percentage than in the general population.1 Additionally, clinical research has shown that treating sleep apnea with continuous positive airway pressure (CPAP) treatment significantly reduces postprandial glucose levels and improves insulin sensitivity in diabetes patients.2,3 Due to these significant interactions, ResMed is working to build relationships between the sleep medicine and diabetes education communities with the goal of implementing practical solutions for sleep apnea among this patient population. "As an educator, I work closely with my patients to help them live a long and healthy life and manage their diabetes - and that includes getting enough sleep," stated Martha M. Funnell, MS, RN, CDE of the Michigan Diabetes Research and Training Center .
ResMed will be exhibiting at booth #1301 at the AADE Annual Meeting in Los Angeles . The conference will take place August 9 through August 12, 2006. The exhibition is part of ResMed's industry awareness campaign to educate healthcare professionals on the relationship between diabetes and sleep apnea, and the potentially serious health risks associated with untreated sleep apnea in diabetes patients. The company is sponsoring an Industry Theatre including a presentation for hundreds of diabetes educators, which will cover an overview of sleep apnea, how to identify symptoms and screen patients, as well as successful management of sleep apnea therapy.
"More than 50% of male diabetes patients and 20% of female diabetes patients have sleep apnea, yet a startling number remain undiagnosed and untreated in practice. As awareness increases about the benefits of CPAP treatment for diabetes patients with sleep apnea, there is a tremendous opportunity for diabetes specialists to improve their patients' treatment outcomes and overall quality of life," said Michael Farrell , Vice President of Marketing. "We look forward to meeting educators at the exhibition booth at AADE and discussing practical ways for diabetes educators to work with sleep centers to reduce their patients' health risk by screening and treating sleep apnea."
For more information, contact Brooke Harding at ResMed by phone at (858) 746-2400 extension 2579, by email at firstname.lastname@example.org, or by visiting the company's multilingual website at www.resmed.com.
ResMed is a leading manufacturer of medical equipment for the screening, treatment and management of sleep-disordered breathing (SDB), selling a comprehensive range of products in over 60 countries. ResMed provides quality systems, reliable products and complete solutions. We are dedicated to improving the lives of people suffering from SDB with effective therapy and lasting results.
1 Einhorn. APSS 2005
2 Babu. Arch Int Med 2005
3 Harsch. AJRCCM 2003